GEHC Stock Analysis: GE HealthCare Technologies | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 29.527m USD | 12M Return: -16.2% | US36266G1076 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 235M
EPS Trend: 84.2%
Qual. Beats: 0
Rev. Trend: 82.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 3.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GE HealthCare Technologies Inc. (GEHC) is a U.S.-based medical technology company that develops, manufactures, and markets diagnostic imaging equipment, patient care devices, and pharmaceutical diagnostics used in hospitals and clinical settings worldwide. The business is organized into four segments: Imaging (CT, MR, X-ray, molecular imaging), Advanced Visualization Solutions (ultrasound and image-guided therapies), Patient Care Solutions (monitoring, cardiology, anesthesia, and maternal/infant care), and Pharmaceutical Diagnostics (contrast media and radiopharmaceuticals for imaging scans). The company maintains a strategic collaboration with DeepHealth and was incorporated in 2022 after spinning off from General Electric, with its IPO completed in January 2023.
GEHC operates in the medical devices and diagnostics sector, selling primarily to hospitals, imaging centers, and radiology departments under a hybrid model that combines capital equipment sales with recurring revenue from consumables, contrast agents, and service contracts. The pharmaceutical diagnostics segment, in particular, generates relatively predictable recurring revenue because contrast media and radiopharmaceuticals are single-use products required for each imaging procedure.
- Imaging orders accelerate as hospital capital spending rebounds
- Contrast media supply tightness lifts PDx pricing and margins
- Share buybacks and margin expansion drive earnings growth
| Net Income: 1.59b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.01 > 1.0 |
| NWC/Revenue: 0.82% < 20% (prev 5.85%; Δ -5.02% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.42b > Net Income 1.59b |
| Net Debt (8.44b) to EBITDA (3.48b): 2.43 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (454.0m) vs 12m ago -0.87% < -2% |
| Gross Margin: 42.91% > 18% (prev 41.55%; Δ 1.37% > 0.5%) |
| Asset Turnover: 55.65% > 50% (prev 56.24%; Δ -0.59% > 0%) |
| Interest Coverage Ratio: 5.66 > 6 (EBIT TTM 2.47b / Interest Expense TTM 436.0m) |
| A: 0.00 (Total Current Assets 8.47b - Total Current Liabilities 8.30b) / Total Assets 37.2b |
| B: 0.17 (Retained Earnings 6.20b / Total Assets 37.2b) |
| C: 0.07 (EBIT TTM 2.47b / Avg Total Assets 36.4b) |
| D: 0.42 (Book Value of Equity 11.0b / Total Liabilities 26.3b) |
| Altman-Z'' = 1.47 = BB |
| DSRI: 0.86 (Receivables 3.88b/4.47b, Revenue 20.2b/20.0b) |
| GMI: 0.97 (GM 41.55% / 42.91%) |
| AQI: 1.13 (AQ_t 0.69 / AQ_t-1 0.61) |
| SGI: 1.01 (Revenue 20.2b / 20.0b) |
| TATA: 0.00 (NI 1.59b - CFO 1.42b) / TA 37.2b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of October 05, 2026, the stock is trading at USD 64.29 with a total of 3,235,164 shares traded. Over the past week, the price has changed by -3.51%, over one month by -8.89%, over three months by -1.89% and over the past year by -16.15%.
Current recommended Stop Loss: 62.00 (which is 3.6% or 1.5 ATR below the current price).
GE HealthCare Technologies has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy GEHC.
- StrongBuy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 83.1 | 29.2% |
P/E Trailing = 15.0622
P/E Forward = 12.1212
P/S = 1.3884
P/B = 2.72
P/EG = 1.6484
Revenue TTM = 20.2b USD
EBIT TTM = 2.47b USD
EBITDA TTM = 3.48b USD
Long Term Debt = 10.1b USD (from longTermDebt, last quarter)
Short Term Debt = 2.00m USD (from shortTermDebt, last quarter)
Debt = 10.5b USD (from shortLongTermDebtTotal, last quarter) + Leases 448.0m
Net Debt = 8.44b USD (calculated: Debt 10.5b - CCE 2.10b)
Enterprise Value = 38.0b USD (29.5b + Debt 10.5b - CCE 2.10b)
Interest Coverage Ratio = 5.66 (Ebit TTM 2.47b / Interest Expense TTM 436.0m)
EV/FCF = 42.42x (Enterprise Value 38.0b / FCF TTM 895.0m)
FCF Yield = 2.36% (FCF TTM 895.0m / Enterprise Value 38.0b)
FCF Margin = 4.42% (FCF TTM 895.0m / Revenue TTM 20.2b)
Net Margin = 7.86% (Net Income TTM 1.59b / Revenue TTM 20.2b)
Gross Margin = 42.91% ((Revenue TTM 20.2b - Cost of Revenue TTM 11.6b) / Revenue TTM)
Gross Margin QoQ = 41.17% (prev 38.53%)
Tobins Q-Ratio = 1.02 (Enterprise Value 38.0b / Total Assets 37.2b)
Interest Expense / Debt = 4.14% (Interest Expense 436.0m / Debt 10.5b)
Taxrate = 21.83% (446.0m / 2.04b)
NOPAT = 1.93b (EBIT 2.47b * (1 - 21.83%))
Current Ratio = 1.02 (Total Current Assets 8.47b / Total Current Liabilities 8.30b)
Debt / Equity = 0.96 (Debt 10.5b / totalStockholderEquity, last quarter 11.0b)
Debt / EBITDA = 2.43 (Net Debt 8.44b / EBITDA 3.48b)
Debt / FCF = 9.43 (Net Debt 8.44b / FCF TTM 895.0m)
Total Stockholder Equity = 10.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.38% (Net Income 1.59b / Total Assets 37.2b)
RoE = 15.16% (Net Income TTM 1.59b / Total Stockholder Equity 10.5b)
RoCE = 11.97% (EBIT 2.47b / Capital Employed (Equity 10.5b + L.T.Debt 10.1b))
RoIC = 6.90% (NOPAT 1.93b / Invested Capital 27.9b)
WACC = 7.62% (E(29.5b)/V(40.1b) * Re(9.18%) + D(10.5b)/V(40.1b) * Rd(4.14%) * (1-Tc(0.22)))
Discount Rate = 9.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.02 | Cagr: -0.49%
[DCF] Terminal Value 73.10% ; FCFF base≈1.16b ; Y1≈1.02b ; Y5≈824.0m
[DCF] Fair Price = 10.61 (EV 13.2b - Net Debt 8.44b = Equity 4.79b / Shares 451.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 84.21 | EPS CAGR: 7.39% | SUE: 0.82 | # QB: 0
Revenue Correlation: 82.55 | Revenue CAGR: 1.42% | SUE: 0.61 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.20 | Chg30d=-0.02% | Revisions=-81% | Analysts=16
EPS current Year (2026-12-31): EPS=4.93 | Chg30d=-0.03% | Revisions=+74% | GrowthEPS=+7.3% | GrowthRev=+5.3%
EPS next Year (2027-12-31): EPS=5.41 | Chg30d=+0.04% | Revisions=+42% | GrowthEPS=+9.9% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: +19% (up=27, down=18)